Scott Law joins Telix as SVP Global Manufacturing Operations
11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations
Telix is delighted to announce that Scott Law has joined the Company as Senior Vice President, Global Manufacturing Operations.
Scott brings with him over 30 years’ global pharmaceutical experience, including senior manufacturing roles at companies such as Baxter, Emergent BioSolutions, Ferndale Laboratories, and Pfizer.
Most recently, Scott served as Vice President, Manufacturing and Operations at Cognate BioServices where he was responsible for the manufacture and commercialization of cell-based products.
Scott will lead Telix’s global manufacturing operations, with an initial focus on final launch preparation for Illuccix® (for prostate cancer imaging).
On joining Telix Scott stated, “It’s exciting to be joining Telix at this pivotal time in the advanced development of life-saving radiopharmaceuticals. I hope to use my experience in commercial pharmaceuticals and biotech to enhance this talented team and deliver products to market.”
We welcome Scott to the Telix team, as we work to deliver on our mission to help patients with cancer live longer, better quality lives.
Illuccix® has not received a marketing authorisation in any jurisdiction.
Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant
Melbourne – 8 August 2022. Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant
Telix 1H 2022 Financial Results and Company Update Investor Call
Melbourne (Australia) – 4 August 2022. Telix to hold investor conference call to present 1H 2022 financial results and Company...
APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging
Melbourne (Australia) – 2 August 2022. Telix announces Regulatory Progress in the APAC Operating Region for Prostate and Kidney Cancer...